Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Status:
RECRUITING
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China